Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This research study will investigate the safety and effectiveness of two different dose
levels of a new, unapproved drug to be given along with the chemotherapy regimens gemcitabine
and carboplatin or gemcitabine and cisplatin prescribed to women for the treatment of ovarian
cancer. This experimental drug is called TXA127 and is being tested for effectiveness to see
if it will help reduce some of the side effects of the chemotherapy, primarily low blood
platelet levels that lead to excess bleeding. This study also intends to test the safety of
TXA127 when given as an injection under the skin on a daily basis concurrently with up to 6
cycles of the prescribed chemotherapy.